Pharsight

Lysteda generic

Lysteda is an anti-bleeding drug owned by Amring Pharmaceuticals. The drug contains the active ingredient tranexamic acid. It was authorized for market use on November 13, 2009 and comes in the form of tablets to be taken orally.

When will Lysteda generic be available?

Lysteda's generic versions are set to be released after March 4, 2025. This is due to the expiration of the last patents which protect the drug formulation from being duplicated by generic manufacturers.

Lysteda uses

Lysteda is used in the treatment of cyclic heavy menstrual bleeding. Its active ingredient, tranexamic acid, helps reduce the loss of blood.

Lysteda patent expiration

Lysteda holds a total of 8 patents, all of which are titled 'Tranexamic acid formulations'. None of these patents have expired as of now. The patents are set to expire on March 4, 2025, after which Lysteda generic versions can be released. Below are the details of the patent:

Lysteda dosage

Want to ask something?